** Shares of drug developer Cytokinetics CYTK.O fall 3.7% to $38.35 premarket
** Rival Bristol Myers Squibb BMY.N said late on Monday its drug, mavacamten, to treat a type of heart disease did not significantly improve functional capacity and symptoms in patients, failing to meet the main goals of a late-stage study
** CYTK is also developing an experimental heart drug, aficamten, to treat non-obstructive form of hypertrophic cardiomyopathy, an inherited condition characterized by thickening of heart muscles
** BofA says most of its prescribers see the two drugs as "more similar than not clinically"
** Brokerage suggests that there might be more discussions about the importance of this class of drugs for all patients, not just those with severe symptoms, due to ongoing uncertainties about the overall potential
** Up to last close, CYTK shares down 15.4%
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.